TWiV 853: COVID-19 clinical update #97 with Dr. Daniel Griffin
Jan 15, 2022•54 min•Ep. 853
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
In COVID-19 clinical update #97, Daniel Griffin covers immunity after infection recognized by CDC, outcomes before and after Omicron, infectious viral load in Delta vs Omicron, PCR vs rapid antigen tests, booster interval shortened to 5 months, risk factors for severe outcomes in vaccinated, cross-reactive memory T cells, vaccine effectiveness vs MIS-C, and Rivaroxiban for thromboprophylaxis.
Subscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Quarantine and isolation (CDC)
- Outcomes before and after Omicron (medRxiv)
- Infectious viral load in Delta vs Omicron infections (medRxiv)
- PCR vs rapid antigen test (medRxiv)
- Booster interval to 5 months (FDA)
- Cross-reactive memory T cells (Nat Comm)
- Risk factors for severe outcomes in vaccinated (MMWR)
- Vaccine effectiveness vs MIS-C (MMWR)
- Cross-reactive T cells to Omicron from vaccines (medRxiv)
- Rivaroxiban for thromboprophylaxis (Lancet)
- Letters read on TWiV 853
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv
For the best experience, listen in Metacast app for iOS or Android